The Q1 2026 filing reveals a company at a binary crossroads. On one side is a strategic evolution into the cannabinoid sector that could provide a legitimate operating base and resolve systemic balance sheet issues. On the other is a terminal decline marked by near-zero revenues and a mountain of convertible debt and preferred obligations that threaten to overwhelm the entity.
The immediate focus for investors is the window between now and January 29, 2027, the deadline to regain NYSE compliance. The success of the Medterra acquisition is not just a growth story but a survival requirement. Until Splash can demonstrate a closed transaction and a funded path to extinguish its senior debt, the stock remains a speculative bet on a reverse-merger turnaround against a backdrop of extreme financial fragility.